- Home
- EML vs GUTS Comparison
EML vs GUTS Comparison
Compare EML & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- GUTS
- Stock Information
- Founded
- EML 1858
- GUTS 2010
- Country
- EML United States
- GUTS United States
- Employees
- EML N/A
- GUTS N/A
- Industry
- EML Industrial Machinery/Components
- GUTS
- Sector
- EML Consumer Discretionary
- GUTS
- Exchange
- EML Nasdaq
- GUTS NYSE
- Market Cap
- EML 141.7M
- GUTS 58.8M
- IPO Year
- EML N/A
- GUTS 2024
- Fundamental
- Price
- EML $23.29
- GUTS $1.62
- Analyst Decision
- EML
- GUTS Buy
- Analyst Count
- EML 0
- GUTS 1
- Target Price
- EML N/A
- GUTS $10.00
- AVG Volume (30 Days)
- EML 12.1K
- GUTS 916.8K
- Earning Date
- EML 08-05-2025
- GUTS 08-13-2025
- Dividend Yield
- EML 1.89%
- GUTS N/A
- EPS Growth
- EML N/A
- GUTS N/A
- EPS
- EML N/A
- GUTS N/A
- Revenue
- EML $271,440,503.00
- GUTS $60,000.00
- Revenue This Year
- EML $1.56
- GUTS N/A
- Revenue Next Year
- EML $7.00
- GUTS N/A
- P/E Ratio
- EML $11.13
- GUTS N/A
- Revenue Growth
- EML 8.15
- GUTS N/A
- 52 Week Low
- EML $19.06
- GUTS $0.87
- 52 Week High
- EML $35.03
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- EML 49.74
- GUTS 46.09
- Support Level
- EML $22.72
- GUTS $1.64
- Resistance Level
- EML $23.39
- GUTS $1.82
- Average True Range (ATR)
- EML 0.49
- GUTS 0.22
- MACD
- EML -0.05
- GUTS -0.07
- Stochastic Oscillator
- EML 48.32
- GUTS 12.22
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.